{"id":"estradiol-drospirenone","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Breakthrough bleeding"},{"rate":"5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":{"setId":"0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37","title":"OCELLA (DROSPIRENONE AND ETHINYL ESTRADIOL) KIT [TEVA PHARMACEUTICALS USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Estradiol (a natural estrogen) and drospirenone (a progestin with antimineralocorticoid activity) inhibit the release of gonadotropin-releasing hormone (GnRH), which prevents the surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) needed for ovulation. Drospirenone additionally provides progestational effects and mild antimineralocorticoid activity, enhancing contraceptive efficacy and providing additional benefits such as reduced bloating.","oneSentence":"Estradiol and drospirenone work together as a hormonal contraceptive by suppressing ovulation through negative feedback on the hypothalamic-pituitary-ovarian axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:50.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Treatment of premenstrual dysphoric disorder (PMDD)"}]},"trialDetails":[{"nctId":"NCT07235774","phase":"PHASE1","title":"A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-11-05","conditions":"Healthy Adult Female Participants","enrollment":28},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07229209","phase":"NA","title":"Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-02-05","conditions":"Abnormal Uterine Bleeding, Cesarean Section Complications, Uterine Scar","enrollment":166},{"nctId":"NCT07340190","phase":"PHASE1","title":"A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Advanced Malignancies","enrollment":24},{"nctId":"NCT07318337","phase":"NA","title":"Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-07-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":60},{"nctId":"NCT07242131","phase":"NA","title":"Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS","status":"RECRUITING","sponsor":"Ege University","startDate":"2025-12-01","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":150},{"nctId":"NCT03819140","phase":"PHASE4","title":"Continuous Versus Cyclical OCP Use in PCOS","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-01","conditions":"Polycystic Ovary Syndrome","enrollment":51},{"nctId":"NCT07204093","phase":"","title":"Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2025-08-11","conditions":"Endometriosis","enrollment":138},{"nctId":"NCT07181343","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)","status":"COMPLETED","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-05-28","conditions":"Psoriasis (PsO)","enrollment":18},{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT06028555","phase":"","title":"International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2023-06-28","conditions":"Contraception, Birth Control","enrollment":101000},{"nctId":"NCT07061093","phase":"","title":"Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational Study","status":"RECRUITING","sponsor":"Ospedale Policlinico San Martino","startDate":"2023-10-10","conditions":"Cardiovascular System Diseases (&Amp; [Cardiac])","enrollment":96},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT06396221","phase":"NA","title":"\"Quick-starting\" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-05-01","conditions":"Ultrasound Finding: Ovulation Inhibition, Ovarian Activities, Cervical Mucus, Serum Hormonal Profile","enrollment":36},{"nctId":"NCT05706753","phase":"PHASE1","title":"A Study of Milvexian in Healthy Adult Females","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2023-01-25","conditions":"Healthy Female","enrollment":20},{"nctId":"NCT02636972","phase":"","title":"The Progression From Dysmenorrhoea to Chronic Pelvic Pain","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2014-11","conditions":"Dysmenorrhoea, Pelvic Pain, Chronic Pain","enrollment":56},{"nctId":"NCT05934942","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-08","conditions":"Healthy","enrollment":29},{"nctId":"NCT06608186","phase":"PHASE1, PHASE2","title":"Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!","status":"COMPLETED","sponsor":"Ahmed Saad","startDate":"2024-10-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":50},{"nctId":"NCT05098574","phase":"PHASE2","title":"Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2023-02-03","conditions":"Premenstrual Dysphoric Disorder, Bipolar Disorder","enrollment":17},{"nctId":"NCT06250205","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-02-05","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06577974","phase":"NA","title":"Role of Medical Treatment in Endometriosis Patients Undergoing ICSI","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Endometriosis","enrollment":129},{"nctId":"NCT06039826","phase":"PHASE1","title":"A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-12","conditions":"Overweight","enrollment":46},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT05872425","phase":"NA","title":"Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS","status":"COMPLETED","sponsor":"Guangdong Women and Children Hospital","startDate":"2023-02-01","conditions":"PCOS","enrollment":120},{"nctId":"NCT06324851","phase":"PHASE4","title":"The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":"Endometrial Polyp, Endometrial Diseases","enrollment":150},{"nctId":"NCT06316180","phase":"PHASE4","title":"The Use of Drospirenone/Estetrol in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":"Endometrial Polyp, Endometrial Diseases","enrollment":80},{"nctId":"NCT06233071","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®","status":"RECRUITING","sponsor":"Bio-innova Co., Ltd","startDate":"2024-02-13","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT06233058","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-03-05","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT05985590","phase":"PHASE1","title":"A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-18","conditions":"Healthy Volunteers","enrollment":37},{"nctId":"NCT06083935","phase":"PHASE4","title":"Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-11-01","conditions":"Poly Cystic Ovary Syndrome","enrollment":120},{"nctId":"NCT03074045","phase":"PHASE3","title":"LCS16 vs. COC User Satisfaction and Tolerability Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-03-13","conditions":"Contraception","enrollment":145},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT04984070","phase":"NA","title":"Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Depression, Anxiety","enrollment":100},{"nctId":"NCT04278755","phase":"PHASE2","title":"Binge Eating & Birth Control","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-09-24","conditions":"Bulimia Nervosa, Binge Eating, Eating Disorders","enrollment":8},{"nctId":"NCT04831151","phase":"NA","title":"The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics","status":"UNKNOWN","sponsor":"Inonu University","startDate":"2021-03-01","conditions":"Polycystic Ovary Syndrome","enrollment":42},{"nctId":"NCT00413062","phase":"PHASE3","title":"Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Contraception","enrollment":2281},{"nctId":"NCT00511433","phase":"PHASE3","title":"Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Contraception","enrollment":48},{"nctId":"NCT00511199","phase":"PHASE3","title":"Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05-01","conditions":"Contraception","enrollment":2152},{"nctId":"NCT05156879","phase":"PHASE4","title":"Aspirin for the Management of Endometriosis-associated Pelvic Pain","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2021-12-23","conditions":"Pelvic Pain","enrollment":220},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":"Follicle Development, Ovarian Follicle, Follicle Count","enrollment":206},{"nctId":"NCT05135013","phase":"","title":"The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study","status":"UNKNOWN","sponsor":"NewGiza University","startDate":"2021-11-16","conditions":"Observational Study","enrollment":200},{"nctId":"NCT03126773","phase":"","title":"A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-02","conditions":"Menopause","enrollment":1570},{"nctId":"NCT04256200","phase":"PHASE2, PHASE3","title":"Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2017-02-07","conditions":"Endometriosis","enrollment":100},{"nctId":"NCT03890341","phase":"PHASE1","title":"Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-01","conditions":"Healthy","enrollment":""},{"nctId":"NCT01805817","phase":"PHASE4","title":"Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality","status":"WITHDRAWN","sponsor":"Istanbul Training and Research Hospital","startDate":"2012-12","conditions":"Contraceptive Methods Comparison","enrollment":""},{"nctId":"NCT01519401","phase":"NA","title":"Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2010-02","conditions":"Polycystic Ovary Syndrome, Estro-progestin Drugs","enrollment":50},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT04296422","phase":"NA","title":"Different Does of Acupuncture on Premenstrual Syndrome Efficacy Analysis","status":"UNKNOWN","sponsor":"Taipei City Hospital","startDate":"2019-01-01","conditions":"Premenstrual Syndrome","enrollment":105},{"nctId":"NCT02817841","phase":"PHASE3","title":"E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-08-30","conditions":"Contraception","enrollment":2148},{"nctId":"NCT03418363","phase":"PHASE4","title":"How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-01-16","conditions":"Contraceptive Usage, Coagulation","enrollment":15},{"nctId":"NCT03843736","phase":"PHASE3","title":"The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-02-21","conditions":"Polycystic Ovary Syndrome","enrollment":200},{"nctId":"NCT02817828","phase":"PHASE3","title":"E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-06","conditions":"Contraception","enrollment":1577},{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT00745901","phase":"PHASE4","title":"Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2008-05","conditions":"Contraception","enrollment":355},{"nctId":"NCT03881319","phase":"NA","title":"The Efficacy of Different Doses of Acupuncture in Dysmenorrhea","status":"UNKNOWN","sponsor":"Taipei City Hospital","startDate":"2018-06-01","conditions":"Premenstrual Syndrome, Dysmenorrhea","enrollment":105},{"nctId":"NCT01375998","phase":"","title":"YAZ Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06-09","conditions":"Dysmenorrhea","enrollment":3273},{"nctId":"NCT01195974","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-09-14","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":13},{"nctId":"NCT02957630","phase":"PHASE1, PHASE2","title":"\"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\"","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-09","conditions":"Contraception, Liver Metabolism, Hemostasis Parameter","enrollment":101},{"nctId":"NCT00640224","phase":"PHASE4","title":"Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study","status":"COMPLETED","sponsor":"Silva Arslanian","startDate":"2005-03","conditions":"Polycystic Ovary Syndrome","enrollment":65},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT01557023","phase":"PHASE3","title":"Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2013-07-01","conditions":"Metrorrhagia","enrollment":""},{"nctId":"NCT03111511","phase":"PHASE1","title":"A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2017-03-27","conditions":"Healthy","enrollment":18},{"nctId":"NCT03126097","phase":"PHASE1","title":"A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-13","conditions":"Healthy","enrollment":18},{"nctId":"NCT00089414","phase":"PHASE2","title":"Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives","status":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2004-07","conditions":"Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder","enrollment":5},{"nctId":"NCT02841202","phase":"PHASE4","title":"The Effect of Oral Contraceptive Pills On Eyes","status":"COMPLETED","sponsor":"Kayseri Education and Research Hospital","startDate":"2014-01","conditions":"Adverse Effect of Oral Contraceptives, Subsequent Encounter","enrollment":40},{"nctId":"NCT02159261","phase":"","title":"Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-07-15","conditions":"Contraception","enrollment":1500},{"nctId":"NCT03124524","phase":"PHASE4","title":"Treatment Choice in Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Adana Numune Training and Research Hospital","startDate":"2015-01-15","conditions":"Primary Dysmenorrhea","enrollment":99},{"nctId":"NCT02874248","phase":"PHASE1","title":"E4/DRSP Single and Multiple Dose PK and Early QT Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-05","conditions":"Contraception","enrollment":55},{"nctId":"NCT01360996","phase":"PHASE4","title":"Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08","conditions":"Polycystic Ovary Syndrome","enrollment":64},{"nctId":"NCT00633360","phase":"NA","title":"The Oral Contraceptive Pill for Premenstrual Worsening of Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-02","conditions":"Premenstrual Syndrome, Depression","enrollment":32},{"nctId":"NCT03037944","phase":"EARLY_PHASE1","title":"Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2016-03-01","conditions":"Adenomyosis","enrollment":32},{"nctId":"NCT02885454","phase":"PHASE1","title":"To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02488538","phase":"PHASE3","title":"Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-07","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT00927095","phase":"PHASE4","title":"Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-07","conditions":"Premenstrual Dysphoric Disorder","enrollment":67},{"nctId":"NCT02855294","phase":"PHASE4","title":"The Effect of Oral Contraceptives on Women Balance","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-01","conditions":"Joint Stabilioty","enrollment":100},{"nctId":"NCT01109979","phase":"PHASE4","title":"Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2009-12","conditions":"Cardiovascular Diseases","enrollment":24},{"nctId":"NCT02562053","phase":"PHASE3","title":"Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-10","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT02757469","phase":"NA","title":"Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure","status":"UNKNOWN","sponsor":"Navy General Hospital, Beijing","startDate":"2016-05","conditions":"Primary Ovarian Insufficiency, Menopause, Premature","enrollment":20},{"nctId":"NCT01902264","phase":"PHASE3","title":"Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-08","conditions":"Contraception","enrollment":34},{"nctId":"NCT02681536","phase":"NA","title":"Miniflare Versus Long Protocol in Poor Responders","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2016-02","conditions":"Infertility","enrollment":200},{"nctId":"NCT01697111","phase":"PHASE3","title":"Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Endometriosis","enrollment":312},{"nctId":"NCT02617537","phase":"PHASE3","title":"To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-01","conditions":"Dysmenorrhea","enrollment":""},{"nctId":"NCT00923572","phase":"","title":"Yasmin Post Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Contraception","enrollment":777},{"nctId":"NCT02384408","phase":"PHASE4","title":"Hormone Replacement Therapy on the Postmenopausal Endometrium","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2014-11","conditions":"Menopause","enrollment":100},{"nctId":"NCT01892904","phase":"PHASE3","title":"Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07","conditions":"Dysmenorrhea","enrollment":216},{"nctId":"NCT00818519","phase":"PHASE3","title":"GA YAZ ACNE in China Phase III","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":179},{"nctId":"NCT02089620","phase":"PHASE3","title":"Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2014-05","conditions":"Premenstrual Syndrome","enrollment":210},{"nctId":"NCT00420342","phase":"PHASE2","title":"Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-01","conditions":"Postmenopause, Hypertension, Pre-Hypertension","enrollment":92},{"nctId":"NCT00283816","phase":"PHASE3","title":"Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2006-01","conditions":"Polycystic Ovary Syndrome","enrollment":36},{"nctId":"NCT00714233","phase":"PHASE3","title":"Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2002-08","conditions":"Polycystic Ovary Syndrome","enrollment":43},{"nctId":"NCT00446199","phase":"PHASE3","title":"Low-dose Hormone Therapy for Relief of Vasomotor Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Vasomotor Symptoms, Hot Flashes","enrollment":735},{"nctId":"NCT00653614","phase":"PHASE2","title":"Cycle Control and Safety of E2-DRSP","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-03","conditions":"Contraceptive, Oral, Hormonal","enrollment":635},{"nctId":"NCT01608698","phase":"PHASE4","title":"Comparison of Body Weight Change During Contraception With Belara and Yasmin","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-06","conditions":"Body Weight Changes","enrollment":100},{"nctId":"NCT00998257","phase":"","title":"Regulatory Post Marketing Surveillance Study on YAZ","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-07","conditions":"Contraception, Premenstrual Syndrome, Acne","enrollment":770},{"nctId":"NCT00185484","phase":"PHASE3","title":"Efficacy and Safety Oral Contraceptive Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":1113},{"nctId":"NCT00522873","phase":"PHASE3","title":"Endometrial Safety Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Postmenopause","enrollment":662},{"nctId":"NCT00651599","phase":"PHASE3","title":"Treatment of Vasomotor Symptoms in Korean Post Menopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Vasomotor Symptoms","enrollment":90},{"nctId":"NCT00624130","phase":"PHASE3","title":"Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":453},{"nctId":"NCT00651846","phase":"PHASE4","title":"Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT00656981","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":541}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"EOSINOPHILIA"},{"count":3,"reaction":"DRUG INTERACTION"},{"count":3,"reaction":"PERICARDIAL EFFUSION"},{"count":3,"reaction":"PERICARDITIS"},{"count":2,"reaction":"DRUG LEVEL INCREASED"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":2,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Angeliq"],"phase":"marketed","status":"active","brandName":"Estradiol+Drospirenone","genericName":"Estradiol+Drospirenone","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estradiol and Drospirenone are components of an oral contraceptive pill, which is used for contraception and the prevention of pregnancy. The combination of Estradiol and Drospirenone is also studied for its effects on various conditions, including cardiovascular diseases and adverse effects of oral contraceptives.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-09-28T00:00:00.000Z","mah":"BAYER HLTHCARE","brand_name_local":"ANGELIQ","application_number":"NDA021355"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}